Quantcast

Latest biopharmaceutical Stories

2014-05-09 08:26:09

CAMEO Phase 2 Clinical Trial of LUM001 Now Enrolling Adults with Primary Sclerosing Cholangitis SAN DIEGO, May 9, 2014 /PRNewswire/ -- Lumena Pharmaceuticals (Lumena), a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, today announced the dosing of the first patient in the INDIGO Phase 2 clinical trial of its lead drug candidate, LUM001, in children with progressive...

2014-05-09 08:25:32

BOSTON, May 9, 2014 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that its Chairman and CEO, Josef von Rickenbach, was named 2014 Immigrant Entrepreneur of the Year in Life Sciences by the Immigrant Learning Center of Malden, Mass. He received the award May 8, 2014, during the third annual Immigrant Entrepreneur Awards Dinner in Cambridge, Mass. A native of Switzerland, Mr. von Rickenbach earned a...

2014-05-07 08:32:51

LA JOLLA, Calif., May 7, 2014 /PRNewswire/ -- Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the expansion of its Board of Directors with the appointment of two new members: -- Lynn D. Bleil, former leader of McKinsey & Company's West Coast Healthcare Practice and a leader of the worldwide Healthcare Practice --...

2014-05-07 08:32:47

MONROVIA, Calif., May 7, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter financial results after market close on Wednesday, May 14, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial...

2014-05-06 16:33:13

JUPITER, Fla., May 6, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today that they have strengthened their European leadership team with the addition of two senior level positions. (Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO...

2014-05-06 16:28:42

LONDON, May 6, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Cell Culture: The Market for Media, Sera and Reagents, 5th Edition http://www.reportbuyer.com/pharma_healthcare/diagnostics/cell_culture_market_media_sera_reagents_5th_edition.htmlThe growth in biopharmaceuticals is creating an unprecedented increase in demand for cell culture products. Cell culture techniques have been used in biological sciences for more than 50 years; however, cell culture...

2014-05-06 04:23:34

SEATTLE, May 6, 2014 /PRNewswire/ -- CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics'...

2014-05-05 08:27:46

SANTA ROSA, Calif., May 5, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the underwriters of Ruthigen's recently completed initial public offering have partially exercised their option to purchase additional shares of common stock. The underwriters have purchased an additional...

2014-05-05 08:27:39

Conference Call and Webcast to Follow THE WOODLANDS, Texas, May 5, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, will release its first quarter 2014 financial results on Thursday, May 8, 2014 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the first quarter...

2014-05-01 12:31:52

Spin-off Would Allow Cytocom to Operate as a Separate Biotechnology Company Focused on Development of LDN and MENK Immunotherapy Products ORLANDO, Fla., May 1, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or the "Company"), a biopharmaceutical company focused on the development, marketing and distribution of opioid-related immunotherapies, announced that its board of directors has approved a plan to spin off its wholly-owned subsidiary, Cytocom, Inc. ("Cytocom"), an entity...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'